R. Wendel Naumann, MD

home / authors / r-wendel-naumann-md

Articles

Dr Naumann on the Changing Treatment Landscape in Cervical Cancer

May 16th 2023

R. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.

Dr. Naumann on the Evolution of Immunotherapy in Endometrial Cancer

R. Wendel Naumann, MD

October 5th 2021

R. Wendel Naumann, MD, discusses the evolution of immunotherapy in endometrial cancer.

Dr. Naumann on the TOPACIO Trial With Pembrolizumab/Niraparib in Ovarian Cancer

R. Wendel Naumann, MD

January 12th 2021

R. Wendel Naumann, MD, discusses the significance of the phase 1/2 TOPACIO trial in ovarian cancer.

Dr. Naumann on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

R. Wendel Naumann, MD

May 6th 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses unanswered questions with PARP inhibitors in ovarian cancer.

$Dr. Naumann on Data With STRO-002 in Platinum-Resistant/Refractory Ovarian Cancer$

Dr. Naumann on Data With STRO-002 in Platinum-Resistant/Refractory Ovarian Cancer

R. Wendel Naumann, MD

May 2nd 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

Dr. Naumann on Improving Outcomes With Chemotherapy in Ovarian Cancer

R. Wendel Naumann, MD

September 19th 2018

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses improving outcomes with chemotherapy for the neoadjuvant treatment of patients with ovarian cancer.

Dr. Naumann on Neoadjuvant Chemotherapy in Patients With Ovarian Cancer

R. Wendel Naumann, MD

August 24th 2018

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System, discusses the use of neoadjuvant chemotherapy in patients with ovarian cancer.